PD-L2 is a second ligand for PD-1 and inhibits T cell activation

By Y. Latchman, C. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Yoshiko Iwai, A. Long, Julia A. Brown, Raquel Nunes and 11 more. Nature Immunology, 2001

2,945 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ee91322c7ff00ab6667efd602c54603361b82ced

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy (2005, background): “described in a wide range of murine and human tissues including placenta, heart, pancreas, spleen, lymph node, and thymus [24, 35, 45, 51], while it was absent in brain and kidney tissue.”
Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection (2006, background): “It is possible that stimulation through PD-1 can direct cells into a cell cycle resting state, as has been described for the PD-1–PD-L2 interaction (21).”
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016, neutral): “ORR 24 (18) 12 to 26 9 (32) 16 to 52 15 (14) 8 to 23 11 (15) 8 to 24 4 (14) 4 to 33 Best overall response CR 4 (3) 1 to 8 3 (11) 2 to 28 1 (1) 0 to 5 1 (1) 0 to 71 0 (0) 0 to 12 PR 20 (15) 10 to 22 6 (21) 8 to 41 14 (14) 8 to 22 10 (13) 7 to 23 4 (14) 4 to 33 SD 26 (20) 13 to 28 4 (14) 4 to 33 22 (2”
Combination of CTLA-4 and PD-1 blockers for treatment of cancer (2019, background): “The ligands for PD-1, PD-L1 (B7-H1) and PD-L2 (B7-DC) are commonly expressed on macrophages and DCs [41, 42].”
The PD-1 Pathway in Tolerance and Autoimmunity (2010, background): “The PD-L2 cytoplasmic domain is short in rodents (only four amino acids) but is longer (approximately 30 amino acids) and conserved in other mammals without any apparent signaling motifs (32, 33).”
PD-1 signaling in primary T cells (2009, background): “Others have found that containing tyrosine phosphatase (SHP)-2 is recruited to the PD-1 cytoplasmic tail in a B-cell line (46) and in Jurkat T cells (47).”
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005, background): “On the other hand, B7-H1, as well as its homologue ligand, B7-DC (22, 23), is capable of costimulating growth of T cells from PD-1 /”
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity (2010, background): “Third, PD-L1 is expressed at high levels in several different cancers (Latchman et al., 2001; Dong et al., 2002; Brown et al., 2003), and high expression of PD-L1 on tumors is strongly associated with poor prognosis (Thompson et al., 2006).”